FINNENCE ▪ THE WIRE FILE
THE WIRE · № 58564
News▲ Bullish
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 22:00 UTC
LAST UPDATE2026-09-30 22:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Oral GLP-1 with cardiovascular safety data strengthens Lilly's competitive position.
Oral GLP-1 safety data supports Lilly's pipeline
CATALYST TO WATCH
Regulatory filing and approval timeline
MAIN RISK
Competitor oral GLP-1 data
FULL DISPATCH
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57%...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
→CORRELATIONshares Healthcare
FIRST-IN-HUMAN STUDY DEMONSTRATES Qi601 CAN PHYSICALLY CAPTURE MICROPLASTICS2026-09-30 23:32 UTC
FIRST-IN-HUMAN STUDY DEMONSTRATES Qi601 CAN PHYSICALLY CAPTURE MICROPLASTICS2026-09-30 23:32 UTC
←CORRELATIONshares Healthcare
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
←CORRELATIONshares LLY
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes2026-09-30 14:15 UTC
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes2026-09-30 14:15 UTC
←CORRELATIONshares LLY
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
←CORRELATIONshares LLY
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial2026-09-30 14:32 UTC
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial2026-09-30 14:32 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.